The major depressive disorder (MDD) therapy market is mature, with numerous safe and effective treatment options available as inexpensive generics, which presents a challenge for branded agents attempting to gain traction in the United States. Nevertheless, the MDD population’s heterogenous response to treatment—and the need for additional efficacious therapies—gives new branded agents the opportunity to be incorporated into the treatment algorithm. This claims data analysis provides insights into how both long-established and newer-to-market agents fit into this crowded and competitive drug market.
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States
Key companies: AbbVie, Janssen, Lundbeck, Otsuka Pharmaceutical, Sunovion, Takeda Pharmaceutical
Key drugs: aripiprazole, bupropion, duloxetine, Latuda, Rexulti, sertraline, Spravato, Trintellix, Viibryd, Vraylar